The emergent knowledge of molecular tumor profiles e.g., EGFR and KRAS mutations and ALK rearrangements for instance raises logistic and algorithmic considerations to approaching the molecular management of the adenocarcinoma subtype of NSCLC. This evidence concerns the gene KRAS and neoplasm.